Gilteritinib (ASP2215)

Catalog No.S7754

Gilteritinib (ASP2215) Chemical Structure

Molecular Weight(MW): 552.71

Gilteritinib(ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).

Size Price Stock Quantity  
USD 127 In stock
USD 427 In stock
USD 890 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 1 publication

Purity & Quality Control

Choose Selective FLT3 Inhibitors

Biological Activity

Description Gilteritinib(ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).
Targets
FLT3 [1]
(Cell-free assay)		 Axl [1]
(Cell-free assay)
0.29 nM 0.73 nM
In vitro

Gilteritinib demonstrates potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3. Gilteritinib decreases the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models. Gilteritinib inhibits the activity of eight of the 78 tested kinases by over 50% at concentrations of either 1 nM (FLT3, LTK, ALK, and AXL) or 5 nM (TRKA, ROS, RET, and MER)[1]. Gilteritinib treatment for 48h results in an induction of apoptosis in MV4-11 cells as determined by an increase in annexin V-positive cells. Gilteritinib also decreases the expression of anti-apoptotic proteins such as MCL-1, BCL2L10, and survivin, which are reported to be important in chemotherapy sensitivity, following 24h treatment[2].
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4-11 cells NVGzSYxZS2WubDDjfYNt\SCjc4PhfS=> M1;tZ|EtKDNuIEGwMEBidmRiM{Cgcm0> M4DVe|I1KGh? M4\UbnRp\SCvZXHuJJBzd3CxcoTpc44hd2ZiTW[0MVEyKGOnbHzzJIlvKEdzIIDoZZNmKHencnWgd4lodmmoaXPhcpRtgSCrbnPy[YF{\WRiYYSg[4ltfGW{aYTpcoljKGOxbnPlcpRz[XSrb37zJI9nKDNiKE[5MlAmQyCSPECuNFEqKGGwZDCxNEBvVSBqN{CuO{U8KFB:MD6wNFEqNg>? Ml3uN|ExPjlyMUW=
MOLM-13 cells M{HHfmFxd3C2b4Ppd{Bie3OjeR?= NWLOPFloOSxiMzygNVAtKDNyLDDhcoQhOTByIH7N NH;DVlA1QCCq MXrzbYdvcW[rY3HueEBqdmO{ZXHz[ZMhcW5idHjlJJBmemOnboTh[4Uhd2ZiYX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{KGG2IHPvcoNmdnS{YYTpc45{KG:oIEOwJI5OKCh|Mj6wKUkh[W6mIEGwNEBvVSBqNUKuOEUqKH[ncoP1d{Bkd262cn;sJEg1NjFnKR?= M4HvfFMyODZ7MEG1
32D/TKD cells NHXWXlZHfW6ldHnvckBie3OjeR?= M2OxPVUxKG6PwrC= MVW2JIg> NGnycJNKdmirYnn0c44hd2ZidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCc3Rib36gWFMxQA>? NV[yXpJCOjl3MEe2OlA>
TF-1 cells NW\BS2hUTnWwY4Tpc44h[XO|YYm= NX;KNYhSOCxiMkCsJFgxNCB{MECgZY5lKDVyMDDuUS=> NX7hcVJTOSCq NF60fmdocWy2ZYLpeIlvcWJiaHHzJIFvKEmFNUCgZYdicW6|dDD3bYxlNXS7cHWgZ{1McXRib3[gNVAzKG6P MV2yO|kxQDh6MR?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-STAT5 / STAT5 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 28516360     


Immunoblot for phosphorylated AKT, ERK, and STAT5 in gilteritinib-treated MV4–11 cells. Blots from one study, which was done in triplicate, are shown.

p-c-kit / c-kit; 

PubMed: 27908881     


TF-1 cells were treated with increasing concentrations gilteritinib in RPMI/10% FBS for 1 hour. Immunoprecipitation and immunoblotting were performed to detect the phosphorylation status of c-Kit and total c-Kit.

p-FLT3(Y591) / FLT3; 

PubMed: 30344940     


Cells were treated with or without 10 nM gilteritinib, or midostaurin for 6 h, and immunoblotting was performed using the indicated antibodies.

28516360 27908881 30344940
In vivo In vivo, gilteritinib is distributed at high levels in xenografted tumors after oral administration. The decreased FLT3 activity and high intratumor distribution of gilteritinib translates to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML. This antitumor activity is associated with a durable inhibition of phospho-FLT3 and phospho-STAT5. Furthermore, treatment with gilteritinib decreases the leukemic burden and prolongs survival in a mouse IBMT model. No overt toxicity is seen in mouse models treated with gilteritinib[1].

Protocol

Cell Research:

[1]
- Collapse
  • Cell lines: MV4-11 cells
  • Concentrations: 0.1 nM, 1 nM, and 10 nM
  • Incubation Time: 2 h
  • Method:

    MV4-11 cells are treated with DMSO or increasing concentrations of gilteritinib for 2 hours. Immunoprecipitation and immunoblot for phosphorylated FLT3 and total FLT3 are performed.


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: MV4-11 xenografted mice (Nude mice)
  • Formulation: 0.5% methylcellulose solution
  • Dosages: 1 mg/kg, 6 mg/kg, and 10 mg/kg
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (180.92 mM)
Ethanol 85 mg/mL (153.78 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 552.71
Formula

C29H44N8O3
CAS No. 1254053-43-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03730012 Recruiting Drug: gilteritinib|Drug: atezolizumab Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Astellas Pharma Global Development Inc.|Astellas Pharma Inc June 19 2019 Phase 1|Phase 2
NCT03964038 Completed Drug: gilteritinib|Drug: gilteritinib mini tablet Healthy Volunteer Astellas Pharma Global Development Inc.|Astellas Pharma Inc May 21 2019 Phase 1
NCT02456883 Completed Drug: gilteritinib|Drug: 14C-labeled gilteritinib Advanced Solid Tumors|Pharmacokinetics of 14C-labeled Gilteritinib Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 4 2016 Phase 1
NCT02571816 Completed Drug: ASP2215 Hepatic Impairment|Healthy Astellas Pharma Global Development Inc.|Astellas Pharma Inc October 23 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Do you have recommendations for the formulation of giltertinib (ASP-2215) in mice (for in vivo studies)?

  • Answer:

    You can use "5% DMSO+40% PEG 300+5% Tween 80+ddH2O" clear at 5mg/ml as a IP formula.

selleck catalog

FLT3 Signaling Pathway Map

Related FLT3 Products

  • Dovitinib (TKI258) Lactate New

    Dovitinib (TKI258) Lactate is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.

  • AMG 925 New

    AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.

  • PX-478 2HCl New

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Quizartinib (AC220)

    Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 3.

    Features:The most potent cellular FLT3-ITD inhibitor.

  • Dovitinib (TKI-258, CHIR-258)

    Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.

  • ENMD-2076

    ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.

    Features:Multi-target, anti-proliferative, pro-apoptotic activity, anti-angiogenic.

  • KW-2449

    KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFRβ, IGF-1R, EGFR. Phase 1.

    Features:Investigated as a FLT3 inhibitor in clinical trials, with others in early development.

  • Tandutinib (MLN518)

    Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2.

  • Dovitinib (TKI-258) Dilactic Acid

    Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.

  • TCS 359

    TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM.

    Features:Highly potent and selective.

Tags: buy Gilteritinib (ASP2215) | Gilteritinib (ASP2215) supplier | purchase Gilteritinib (ASP2215) | Gilteritinib (ASP2215) cost | Gilteritinib (ASP2215) manufacturer | order Gilteritinib (ASP2215) | Gilteritinib (ASP2215) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID